- Meeting abstract
- Open Access
- Published:
Application of PET/CT to adjuvant chemotherapy for early lung adenocarcinoma
Journal of Cardiothoracic Surgery volume 10, Article number: A198 (2015)
Background/Introduction
The role of adjuvant chemotherapy for stage I lung cancer is unknown. Some Japanese trials demonstrated that tegaful-uracil chemotherapy improved the prognosis of stage I lung cancer over 2 cm.
Aims/Objectives
The purpose of this study is to determine the significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) images to postoperative adjuvant chemotherapy for early lung adenocarcinoma.
Method
We reviewed 174 consecutive patients with completely resected pathological T1b-2aN0M0 lung adenocarcinoma between January 2006 and March 2011, and assessed recurrence-free interval and overall survival based on SUVmax values derived from preoperative FDG-PET/CT images. All patients were assessed by FDG-PET/CT before surgery
Results
Ninety patients received adjuvant chemotherapy and 84 did not. Patients given adjuvant chemotherapy were older, but had the lower T status tumor than patients who were not (both, p < 0.001). Adjuvant chemotherapy conferred benefits upon recurrence-free interval and overall survival compared with observation (p = 0.007 and p = 0.004, respectively). Multivariate Cox proportional hazard analyses revealed SUVmax as an independent prognostic factor for recurrence-free interval (hazard ratio 8.03, p < 0.001). Recurrence-free interval and overall survival were significantly longer for patients who received adjuvant chemotherapy compared with those who did not in the group with SUVmax ≤ 2.6 (p < 0.001 and p < 0.001, respectively). However, recurrence-free interval and overall survival did not significantly differ between such patients in the group with SUVmax < 2.6 (p = 0.421 and p = 0.452, respectively).
Discussion/Conclusion
Preoperative SUVmax on FDG-PET/CT images reflected the efficacy of postoperative adjuvant chemotherapy in patients with pathological T1b-2aN0M0 lung adenocarcinoma. Indications of adjuvant chemotherapy for eraly lung adenocarcinoma might be more precisely determined using SUVmax on FDG-PET/CT images together with tumor size.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Sasada, S., Miyata, Y., Mimae, T. et al. Application of PET/CT to adjuvant chemotherapy for early lung adenocarcinoma. J Cardiothorac Surg 10, A198 (2015). https://doi.org/10.1186/1749-8090-10-S1-A198
Published:
DOI: https://doi.org/10.1186/1749-8090-10-S1-A198
Keywords
- Lung Cancer
- Adenocarcinoma
- Prognostic Factor
- Tumor Size
- Adjuvant Chemotherapy